rejuvant life tabs

Cash challenges for AgeX despite R&D gains

Latest articles

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

New research institute focuses on science of aging

New Bakar Aging Research Institute aims to drive deeply collaborative research to enhance translational medicine, progressing novel therapies from lab to clinic to community. UC...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Can leucine turbo-charge longevity supplements and drugs?

Our exclusive interview with NuSirt’s founder explores how combining the sirtuin-activating amino acid has the potential to enhance the effect of longevity supplements and...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...
Rejuvant

AgeX receives deficiency letter from the Exchange.

AgeX Therapeutics Inc. has announced that it has received a regulatory Deficiency Letter from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet the listing standards of having at least $2,000,000 in stockholders equity and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years.

Longevity.Technology: AgeX has racked-up positive announcements over recent months such as securing a patent for a method of generating induced pluripotent stem cells, and as covered previously by Longevity.Technology, starting work on pluripotent stem cell lines with its immunotolerance UniverCyte technology – taking them a step closer to the the goal of universal allogenic cells.

But the lack of hitting significant revenue or striking lucrative commercial licensing deals is taking its toll. Investor sentiment for Longevity stocks is challenging, as Aubrey de Grey told us: “I think that founders, original early stage investors and boards of directors of start-up companies in this space, need to be really cautious about floating on the stock market.”

Elevant

As a result of the notification, AgeX intends to provide the Exchange with a plan by July 1, 2020 advising on the actions it has taken, and will take, that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. If the Exchange staff does not accept AgeX’s plan, the Exchange staff will commence delisting proceedings.

Elevant

On March 30, 2020, AgeX entered into a Secured Convertible Facility Agreement with Juvenescence Limited which enables AgeX to borrow funds from time to time. On April 1, 2020 AgeX drew-down an initial $500,000.

We wish CEO Mike West and his team the very best in their endeavours of these coming months.

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

Longevity supplements report: Youth & Earth profile

Youth & Earth is keeping it natural, while slowing down aging. Over the coming weeks, we will be bringing you extracts of 11 company profiles...

Longevity supplements report: Juvenescence profile

Ahead of the launch of its first major product, Metabolic Switch, we take a look at Juvenescence. Over the coming weeks, we will be bringing...

Longevity supplements report: ChromaDex profile

We dive into ChromaDex: the company behind the successful nicotinamide riboside supplement Tru Niagen®. Over the coming weeks, we will be bringing you extracts of...
Supps report ad middle